Hydromorphone
In clinical developmentAlso known as Dihydromorfinon, Dihydromorphinone, Dilaudid, Dilaudid Cough+11 more
Dihydromorfinon, Dihydromorphinone, Dilaudid, Dilaudid Cough, Exalgo, Hidromorfona, Hydromorfona, Idromorfone, Palladone, 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one, 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone, 6-Deoxy-7,8-dihydro-6-oxomorphine, 7,8-Dihydromorphinone, HYDROmorphone Hydrochloride, Hydromorphonum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Glutamatergic Mechanisms in Opioid and Cocaine Co-Use
Optimizing Outpatient Anesthesia (OSPREy-Outpatient Surgery Pain Relief Enhancement)
Intranasal hydromorphone for treatment of acute pain in children: A pilot study.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- The American journal of emergency medicine1
- Dayan PS1
- DePeter KC1
- Gordon SL1
- Pan SS1
- Tsze DS1
- Wagh AM1
- Columbia University College of Physicians and Surgeons1
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials